Reading Latitude's success rates

Their site states: "98% of patients under 4 years achieved desensitization to their allergen(s) with oral immunotherapy. 94% of patients of all ages achieved desensitization. Source: Internal data, 2026" — their wording, their label. Earlier materials cited 92% desensitization within one year and 97% for under-fours. Separately, data presented with Weill Cornell at the AAAAI 2025 conference reported that roughly 5% of doses among more than 1,000 OIT patients caused any reaction, the overwhelming majority mild. Latitude also publishes an average of about 8.4 months from starting treatment to reaching maintenance.

It is closer to the opposite — the clinic tells you plainly that the figures come from its own records rather than peer-reviewed research, which is more disclosure than many providers offer. That candor deserves credit and the standard questions in equal measure. Internal data can be entirely accurate and still benefit from the denominator question (does 94% count everyone who started, or everyone who finished?), the definition question (what dose threshold equals desensitization?), and the verification question (has anyone outside the clinic checked?). The AAAAI 2025 collaboration with Weill Cornell partially answers the third question for the safety figure, though a conference abstract is not yet a peer-reviewed publication.

They sit at the strong end of the published literature, which is plausible for a specialized, well-supervised clinic. A peer-reviewed head-to-head study in peanut-allergic children (PMID 25528358) found OIT raised reaction thresholds about 141-fold at 12 months, so high desensitization rates from supervised OIT are consistent with independent research. The same study found OIT caused significantly more adverse reactions and withdrawals than sublingual immunotherapy, which raised thresholds about 22-fold — the trade the whole field runs on: speed and depth versus gentleness. The useful follow-up question for Latitude is what has been formally published since the AAAAI 2025 abstract.

It is a genuinely encouraging figure, gathered with an academic partner across more than 1,000 patients, with the overwhelming majority of reactions described as mild. Note what it measures: reactions per dose, not the share of patients who ever react — a patient doses daily for months, so the per-patient experience is a different number worth asking about. OIT in general carries more frequent anaphylaxis and GI side effects than sublingual dosing, which is why it requires in-person physician observation, and daily life on OIT comes with rules — dose at the same time daily with food, no strenuous exercise or hot showers for two to three hours after, hold doses during illness. See [what each protocol asks of a normal week](/learn/food-immunotherapy-daily-life).

Latitude publishes 6 to 12 months of active treatment to reach maintenance, with an average of about 8.4 months — fast by immunotherapy standards, and a real advantage of supervised in-clinic OIT. Reaching maintenance is not the end, though: Latitude describes lifelong maintenance dosing afterward, and allergy immunotherapy as a field typically runs a 3 to 5 year full course. Desensitization means a raised reaction threshold maintained by ongoing dosing, so the honest way to read "8.4 months" is as the on-ramp to a long-term commitment, not the whole trip.

Latitude's FAQ says diagnostics and visits are typically covered in-network — they list Aetna, Anthem, Blue Shield, Cigna, UnitedHealthcare and others across their California and New York regions — but the one-time OIT program fee is a non-covered service, and the amount is not published. Patients report it: one Bay Area family described "more than $4,000," a New York reviewer put it at over $5,000, so treat it as a $4,000–$5,000+ range by region and date. Payment plans and FSA/HSA funds are accepted. For context, in-person food allergy programs generally can cost $10,000+ per year of treatment; see the [published-figure comparison across clinics](/learn/food-allergy-clinics-compared).

Latitude's practice skews pediatric — the headline figure is specifically about patients under 4 — but adults are treated case by case. One 36-year-old peanut-allergic patient reported being accepted "although they stated they don't normally treat adults," with a cited eligibility threshold of peanut component IgE of 2.0 or greater, and reached maintenance in the standard 6 to 12 months. The 94% all-ages figure includes whatever age mix the clinic actually treated, which is not published — a fair question to ask at your consult if you are an adult patient.

Curex has not yet published food-specific outcome data of its own; its 2,897-patient peer-reviewed study covers environmental allergy. The food program rests on the published peanut-SLIT trials this page cites. In NIH-funded studies at UNC, 67–70% of children on extended peanut SLIT could tolerate 750–800 mg or more of peanut protein and a quarter to a third passed a full 5,000 mg challenge (PMID 31493887; PMID 36828080); in toddlers started at ages 1–4, the median tolerated dose after three years was 4,443 mg against 143 mg on placebo, 60% passed the challenge against none, and 48% showed remission after three months off treatment (PMID 37815782) — with no dose in any of the three studies requiring epinephrine. Our food-program claims — gentler dosing that more patients finish, no confirmed food-program savings amount — deserve the same denominator, definition, and verification questions; ask them. [Is Curex legit](/learn/is-curex-legit) and [how Curex works](/learn/how-curex-works) exist to be checked against outside sources the same way this page checks Latitude. Curex food-plan rates, client commercial terms as of 2026-10-12: Food Allergy Drops: $199/month or $1,990/year. Unlimited number of foods, as clinically prescribed; plus insurance copay for each video consultation. Environmental + Food Allergy Drops: $259/month or $2,590/year. Two treatment sets, with unlimited number of allergens as clinically prescribed; plus insurance copay for each video consultation. Food Drops Self-Pay Plan: $249/month or $2,490/year. Food allergy drops; consultations included without a consultation copay. Environmental + Food Drops Self-Pay Plan: $299/month or $2,990/year. Environmental and food allergy drops; consultations included without a consultation copay. For the listed allergy plans, the annual subscription costs the equivalent of 10 monthly payments instead of 12: two months of subscription fees saved, or 16.7% compared with paying monthly for a year. This is subscription savings, not a discount on testing, copays or your total medical bill. Other products have their own payment terms; GLP-1 annual rates are shown separately. Treatment fees are self-pay. Insurance benefits are verified during onboarding. Each video consultation has a plan-dependent specialist copay, normally $35, which can be lower or higher depending on your plan. Deductibles and coinsurance may also affect your responsibility. The subscription covers compounded allergy drops and non-insured clinic services, including shipping, asynchronous consultations and care management. Insurance-category subscriptions add a copay for each video consultation. The environmental, food and combined self-pay drops plans and the environmental allergy shots plan include consultations without a consultation copay. Certain self-collection tests are not insurance-covered and are priced separately. Allergy IgE, celiac and Alpha-Gal tests may be covered by insurance, depending on your plan. IgG food sensitivity testing is not covered by insurance; the laboratory bills the patient directly. Verify coverage and the laboratory estimate before ordering. See /learn/curex-pricing and confirm eligibility, testing costs and a personalized written quote.

No single figure. The Wisconsin clinic — sublingual drops for food allergy since 1970, more than 275,000 patients, author of the La Crosse Method protocol — points instead to an independent Validation Institute review of its outcome data and to its collaborations with Duke and UNC on peanut SLIT, the NIH-funded studies cited on this page. It treats infants through adults in person in Onalaska, explicitly including anaphylaxis history and uncontrolled asthma.